Brief: AIM Vaccine Says MRNA Respiratory Syncytial Virus Vaccine Obtained Approval
30/10/2024 01:14
Oct 30 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* MRNA RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE OBTAINED
CLINICAL
TRIAL APPROVAL FROM NMPA OF CHINA
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine